Search Results - "Xu, Chong-Rui"

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.

Authors: Wu, Yi-Long Xu, Chong-Rui Hu, Cheng-Ping et al.

Source: OncoTargets & Therapy. Nov2018, Vol. 11, p8575-8587. 13p.

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China.

Authors: Pi, Can Xu, Chong‐Rui Zhang, Ming‐feng et al.

Source: Thoracic Cancer. Jul2018, Vol. 9 Issue 7, p814-819. 6p.

Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.

Authors: Xu, Chong ‐ Rui Zhong, Wen ‐ Zhao Zhou, Qing et al.

Source: Thoracic Cancer. Jan2017, Vol. 8 Issue 1, p51-53. 3p.

Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?—A Case Report.

Authors: Ren, Zi‐Rui Wu, Lv Lu, Chang et al.

Source: Thoracic Cancer. Jan2026, Vol. 17 Issue 1, p1-5. 5p.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Authors: Zhou, Qing Xu, Chong-Rui Cheng, Ying et al.

Source: Cancer Cell. Sep2021, Vol. 39 Issue 9, p1279-1279. 1p.

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

Authors: Chen, Hua-Jun Tu, Hai-Yan Hu, Yanping et al.

Source: Journal of Hematology & Oncology. 1/5/2025, Vol. 18 Issue 1, p1-10. 10p.

Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.

Authors: Deng, Jia-Yi Yang, Ming-Yi Yang, Xiao-Rong et al.

Source: BMC Cancer. 9/27/2024, Vol. 24 Issue 1, p1-11. 11p.

Identification of a risk score model based on tertiary lymphoid structure‐related genes for predicting immunotherapy efficacy in non‐small cell lung cancer.

Authors: Mei, Shi‐Qi Liu, Jia‐Qi Huang, Zi‐Jian et al.

Source: Thoracic Cancer. May2024, Vol. 15 Issue 14, p1119-1131. 13p.

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Authors: Wu, Lin Li, Junling Xu, Chong-Rui et al.

Source: Lung Cancer (01695002). Jan2026, Vol. 211, pN.PAG-N.PAG. 1p.

Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.

Authors: Luo, Wei-Chi Mei, Shi-Qi Huang, Zi-Jian et al.

Source: Journal of Translational Medicine. 4/2/2024, Vol. 22 Issue 1, p1-13. 13p.

Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions.

Authors: Peng, Ying-Long Wang, Zi-Yan Zhong, Ri-Wei et al.

Source: Cancers. Jan2024, Vol. 16 Issue 2, p304. 12p.

Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer.

Authors: Deng, Jia-Yi Gao, Ming Fan, Xue et al.

Source: Cancer Immunology, Immunotherapy. May2025, Vol. 74 Issue 6, p1-11. 11p.

Redox^high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.

Authors: Wei, Xue-Wu Lu, Chang Zhang, Yi-Chen et al.

Source: OncoImmunology. 2024, Vol. 13 Issue 1, p1-14. 14p.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Authors: Maggie Liu, Si-Yang Huang, Jie Deng, Jia-Yi et al.

Source: Science Bulletin. Feb2024, Vol. 69 Issue 4, p535-543. 9p.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.

Authors: Lu, Chang Wei, Xue-Wu Zhang, Yi-Chen et al.

Source: Journal of Cancer Research & Clinical Oncology. Jul2023, Vol. 149 Issue 7, p2987-2995. 9p.

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Authors: Zhang, Chan-Yuan Sun, Hao Su, Jun-Wei et al.

Source: Lung Cancer (01695002). Jan2023, Vol. 175, p68-78. 11p.

Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.

Authors: Chen, Hua‐Jun Yang, Jin‐Ji Fang, Liang‐Yi et al.

Source: Thoracic Cancer. Mar2014, Vol. 5 Issue 2, p155-161. 7p.

High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.

Authors: Bai, Xiao-Yan Lin, Jia-Ying Zhang, Xu-Chao et al.

Source: Cancer Biomarkers. 2013, Vol. 13 Issue 1, p37-47. 11p.

An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer.

Authors: Wang, Kun Zhou, Qing Guo, Ai-Lin et al.

Source: Immunological Investigations. Oct2009, Vol. 38 Issue 7, p665-680. 16p. 1 Color Photograph, 1 Black and White Photograph, 2 Charts, 4 Graphs.

Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.

Authors: Zheng, Mei-Mei Tu, Hai-Yan Yang, Jin-Ji et al.

Source: European Journal of Cancer. Jun2021, Vol. 150, p23-30. 8p.